- March 2011 Data Confirm Strong Treatment Effect of ...
- - Results of Phase III SAVE-ONCO Study Selected for "Best of ASCO 2011" ...
- Phase I Data for NKP-1339, a First-in-Class Transferrin Targeted Anti-Cancer Agent to be Presented at Upcoming ...